A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue
Jeremy J. Theal, Mohssen N. Toosi, Larisa Girlan, Ronald J. Heslegrave, Pierre‐Michel Huet, Kelly W. Burak, Mark Swain, George A. Tomlinson, E. Jenny Heathcote – 24 May 2005 – Fatigue is common in primary biliary cirrhosis (PBC). Altered central serotonergic neurotransmission may be involved in its pathogenesis. This multicenter, randomized, double‐blind, placebo‐controlled, crossover trial evaluated the efficacy of ondansetron, a selective 5‐HT3 receptor subtype antagonist, for treating fatigue in PBC.